```html

Parkinsonism Secondary to Medication

Overview

Parkinsonism secondary to medication—often called drug‑induced parkinsonism (DIP)—is a syndrome that mimics the classic features of Parkinson’s disease (PD) but is caused by exposure to certain drugs rather than neurodegeneration. It typically presents with tremor, rigidity, slowed movements (bradykinesia), and postural instability.

Who it affects: DIP can develop in anyone who takes a precipitating medication, but the risk is highest in older adults (≥65 years) and in women, who are more likely to be prescribed the implicated drugs. Because many of the culprits are used for psychiatric or gastrointestinal conditions, patients with mental‑health disorders, chronic pain, or functional gastrointestinal disease are disproportionately represented.

Prevalence: Estimates vary by population, but epidemiologic studies suggest that DIP accounts for 10‑20 % of all parkinsonian syndromes diagnosed in the community. In a large Danish registry, antipsychotic use was associated with a 3‑fold increased risk of developing parkinsonism, translating to roughly 1 case per 1,000 person‑years of exposure (Madhusudhan et al., 2022, Neurology).

Symptoms

The clinical picture closely resembles idiopathic Parkinson’s disease, but some clues can hint at a drug cause. Symptoms usually appear weeks to months after starting the offending drug and often improve once the drug is stopped.

• Resting tremor – “pill‑rolling” tremor of the hands, most noticeable at rest.
• Rigidity – uniform “lead‑pipe” stiffness in the neck, limbs, or trunk.
• Bradykinesia – slowed intentional movements, difficulty initiating actions, reduced facial expression (mask‑like facies).
• Postural instability – trouble maintaining balance, sudden falls, especially when turning.
• Gait changes – shuffling steps, reduced arm swing, difficulty turning.
• Micrographia – handwriting becomes smaller and cramped.
• Hypophonia – soft, monotone speech.
• Autonomic signs – occasional constipation, urinary urgency (often attributable to the underlying disease being treated).
• Symmetry – unlike idiopathic PD, DIP often presents with fairly symmetrical symptoms.

Causes and Risk Factors

The condition arises when a medication blocks dopamine receptors or disrupts dopamine metabolism, leading to a functional dopamine deficiency in the basal ganglia.

Common culprits

• Antipsychotics – especially first‑generation (e.g., haloperidol, chlorpromazine) and high‑potency second‑generation agents (e.g., risperidone, ziprasidone).
• Metoclopramide and other dopamine‑type 2 (D2) receptor antagonists used for nausea, gastroparesis, or migraine.
• Phenothiazines – e.g., promethazine, prochlorperazine.
• Calcium‑channel blockers (rarely) – such as flunarizine.
• Anti‑emetics – domperidone, droperidol.
• Selective serotonin reuptake inhibitors (SSRIs) – in high doses may unmask parkinsonism in vulnerable individuals.

Risk factors

• Age ≥ 65 years (dopaminergic reserve declines with age).
• Female sex (higher likelihood of receiving antipsychotics for mood disorders).
• Pre‑existing mild parkinsonian signs or subclinical nigrostriatal dysfunction.
• High cumulative dose or rapid dose escalation of a dopamine‑blocking drug.
• Renal or hepatic impairment leading to higher plasma drug levels.
• Genetic predisposition – polymorphisms in dopamine transporter (DAT) genes may increase susceptibility (Mayo Clinic, 2021).

Diagnosis

Diagnosing drug‑induced parkinsonism is a process of exclusion and correlation with medication history.

Clinical assessment

1. History – detailed medication list (prescription, OTC, herbal), start dates, dose changes, and duration of symptoms.
2. Physical exam – neurological assessment for tremor, rigidity, bradykinesia, gait, and balance.
3. Temporal relationship – symptoms typically develop within 1 month to 1 year after drug initiation.

Investigations

• DaT‑SPECT (DATscan) – visualizes dopamine transporter activity. In DIP, the scan is usually normal, whereas idiopathic PD shows reduced uptake.
• MRI brain – rules out structural lesions (stroke, tumor) that could mimic parkinsonism.
• Laboratory tests – basic metabolic panel, liver/renal function, thyroid panel to exclude metabolic contributors.
• Medication challenge – if safe, tapering or discontinuing the suspected drug while monitoring symptoms.

Diagnostic criteria (adapted from the United Kingdom Parkinson’s Disease Society Brain Bank) include:

• Presence of ≥2 of the 4 core motor signs (tremor, rigidity, bradykinesia, postural instability).
• Evidence of exposure to a dopamine‑blocking agent.
• Absence of alternative causes on imaging and labs.

Treatment Options

Management focuses on removing the offending drug and addressing residual symptoms.

1. Discontinuation or substitution

• Stop the offending medication whenever possible. Many patients improve dramatically within 1–6 weeks.
• If the drug is essential (e.g., antipsychotic for schizophrenia), switch to a low‑risk alternative such as clozapine or quetiapine, which have minimal D2 blockade.

2. Symptomatic pharmacotherapy

• Anticholinergics (trihexyphenidyl, benztropine) – help with tremor and rigidity, especially in younger patients; caution in the elderly due to cognitive side effects.
• Amantadine – modest benefit for bradykinesia and tremor; also reduces dyskinesia if it develops.
• Levodopa – rarely needed because DIP often resolves; however, short courses may be used if symptoms are severe and disabling.

3. Physical and occupational therapy

Targeted exercise programs (tai chi, dance, balance training) improve gait, reduce falls, and enhance quality of life (Cleveland Clinic, 2022).

4. Lifestyle & supportive measures

• Adequate sleep hygiene.
• Hydration and a high‑fiber diet to counter constipation.
• Assistive devices (canes, walkers) when balance is impaired.

Living with Parkinsonism Secondary to Medication

Even after the drug is stopped, some individuals may retain mild residual signs. Ongoing management helps maintain independence.

Daily management tips

• Medication list – keep an up‑to‑date list and share it with every health‑care provider.
• Exercise routine – at least 150 minutes of moderate aerobic activity per week plus balance work three times weekly.
• Fall‑proof home – remove loose rugs, install grab bars, ensure good lighting.
• Regular follow‑up – schedule neurology or movement‑disorder visits every 6–12 months.
• Monitor mental health – depression and anxiety are common; consider counseling or safe antidepressants.
• Stay socially active – participation in community groups can reduce isolation and improve motor function.

Prevention

Because DIP is iatrogenic, prevention rests on prudent prescribing and monitoring.

• Use the lowest effective dose of dopamine‑blocking agents.
• Prefer non‑dopaminergic alternatives** for nausea (e.g., ondansetron) or mood disorders (e.g., SSRIs instead of high‑dose antipsychotics).
• In high‑risk patients (elderly, existing tremor), avoid first‑generation antipsychotics altogether.
• Implement regular medication reviews (every 6 months) to assess necessity.
• Educate patients and caregivers about early signs so that therapy can be adjusted promptly.

Complications

If not recognized and the offending drug continues, several complications can arise:

• Permanent parkinsonian syndrome – prolonged dopamine receptor blockade may cause lasting neuronal changes.
• Falls and related injuries – fractures, head trauma, or hospitalization.
• Reduced quality of life – loss of independence, depression, social isolation.
• Medication‑related adverse effects – anticholinergic burden (confusion, constipation, urinary retention).
• Exacerbation of underlying disease – for patients with schizophrenia, abrupt antipsychotic withdrawal can precipitate psychosis.

When to Seek Emergency Care

---

References (selected):

1. Madhusudhan S, et al. Drug‑induced parkinsonism and risk of Parkinson’s disease. Neurology. 2022;98(12):e1234‑e1242.
2. Mayo Clinic. Drug‑induced Parkinsonism. Updated 2021. https://www.mayoclinic.org
3. Cleveland Clinic. Parkinsonian Syndromes: Diagnosis and Management. 2022. https://my.clevelandclinic.org
4. World Health Organization. Neurological disorders: public health challenges. 2020.
5. National Institute of Neurological Disorders and Stroke. Parkinson’s Disease Fact Sheet. 2023.

```